Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEzra E.W. Cohen, Signe Friesland, Mirelis Acosta-Rivera et al.|The Lancet|2018Cited by 1.7k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in OncologyDavid S. Ettinger, Miranda Hughes, Douglas E. Wood et al.|Journal of the National Comprehensive Cancer Network|2022Cited by 1.4k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021David S. Ettinger, Miranda Hughes, Douglas E. Wood et al.|Journal of the National Comprehensive Cancer Network|2021Cited by 1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020David S. Ettinger, Douglas E. Wood, Charu Aggarwal et al.|Journal of the National Comprehensive Cancer Network|2019Cited by 1k
Non–Small Cell Lung Cancer, Version 4.2024Gregory J. Riely, Lisa Hang, Douglas E. Wood et al.|Journal of the National Comprehensive Cancer Network|2024Cited by 746